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Abstract
Background & Aims: There is a paucity of data on the impact of hepatitis D virus (HDV) in patients with hepatitis
B virus (HBV) infection from South Asia. We studied the impact of HDV co-infection on virological and clinical
characteristics.
Methods: We collected data of 480 patients with HBsAg positive and a detectable HBV DNA PCR, who presented
to the Aga Khan University, Karachi and Isra University in Hyderabad, Pakistan in the last 5 years. HDV co-infection
was diagnosed on the basis of anti-HDV. ALT, HBeAg, HBeAb and HBV DNA PCR quantitative levels were checked
in all patients. We divided all patients into two groups based on anti-HDV, and compared their biochemical,
serological & virological labs and clinical spectrum. Clinical spectrum of disease included asymptomatic carrier (AC),
chronic active hepatitis (CAH), immuno-tolerant phase (IP), and compensated cirrhosis (CC).
Results: HDV co-infection was found in 169 (35.2%). There were 164 (34.6%) HBeAg positive and 316 (65.4%)
HBeAg negative patients. Mean ALT level was 66 ± 73 IU. 233 (48.5%) had raised ALT. HBV DNA level was ≥ 10e5
in 103(21.5%) patients. Overall, among HBV/HDV co-infection, 146/169 (86.4%) had suppressed HBV DNA PCR as
compared to 231/311 (74.3%) patients with HBV mono-infection; p-value = 0.002. Among HBeAg negative patients
71/128(55.5%) had raised ALT levels among HBV/HDV co-infection as compared to 71/188 (37.8%) with HBV mono-
infection (p-value = 0.002); levels of HBV DNA were equal in two groups; there were 27/128 (21%) patients with CC
among HBV/HDV co-infection as compared to 23 (12%) in HBV mono-infection (p-value = 0.009); there were less
AC (p-value = 0.009) and more CAH (p-value = 0.009) among HBV/HDV co-infection patients. Among HBeAg
positive patients, serum ALT, HBV DNA levels and the spectrum of HBV were similar in the two groups.
Conclusions: HBV/HDV co-infection results in the suppression of HBV DNA. A fair proportion of HBV/HDV co-
infected patients with HBeAg negative have active hepatitis B infection and cirrhosis as compared to those with
mono-infection.
Introduction
Hepatitis delta virus (HDV) is a satellite RNA virus that
depends on the envelope protein of the hepatitis B virus
(HBV) to enter the hepatocytes and assemble new HDV
particles [1]. Worldwide, more than 350 million people
are considered to have chronic HBV infection, and 15-
20 million of these individuals are thought to be co-
infected or super-infected with HDV [2].
Hepatitis delta is considered to be the most severe
form of viral hepatitis, often leading to the rapid
development of liver cirrhosis. Furthermore HDV infec-
tion has also been linked with a higher risk for the
development of hepatocellular carcinoma [3].
The infection was endemic in the 1970s throughout
Southern Europe, and was responsible for a substantial
proportion of cases of HBsAg- positive liver disorders
[4,5]. However, the prevalence of HDV had substantially
declined in Italy from 23% in 1987 to 8.3% in 1997 as
reported by Stroffolini et al [6]. A similar decline was
noted in Taiwan, with prevalence decreasing from 23.7%
in 1983 to 4.2% in 1996 [7], as well as in Spain and Tur-
key [8]. This decline in prevalence of HDV infection was
achieved by enhancing awareness among the general
public and by measures taken for vaccination against
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hepatitis B in these countries. In Pakistan, however, viral
hepatitis remains a serious health problem. We have
reported the country-wide prevalence of HDV infection
in hepatitis B surface antigen (HBsAg)-positive indivi-
duals to be 16.6% [9]. Very recently, a comprehensive
report on the epidemiology of hepatitis delta in the Asia-
Pacific region was published by Abbas et al [10]. Accord-
ing to this report, prevalence from different parts of Asia
is variable, and ranges from 3-10% in India, 2-20% in
Iran, 18% in Afghanistan and 3-8% in Saudi Arabia.
There are seven HDV genotypes described, and their
nomenclature is defined as type I-VII; various genotypes
are reported to be associated with different long term
outcomes of infection [11]. Recently Moatter et al
reported genotype 1 of HDV and genotype D of HBV
from Pakistan [12], which has also been confirmed on a
larger scale by our group (13).
HBV infection is associated with a broad spectrum of
clinical manifestations, ranging from an asymptomatic
carrier (AC) state to acute liver failure. It can also mani-
fest in diverse forms of chronic infection, including the
immune tolerant phase (IP), chronic active hepatitis B
(CAH), compensated liver cirrhosis (CC), and hepatocel-
lular carcinoma (HCC).
Co-infections of hepatitis B with multiple hepatitis
viruses are associated with diverse patterns of reciprocal
inhibition of viral replication. Delta hepatitis occurs due
to co-infection of HBsAg positive patients with hepatitis
delta virus. There are inconsistent reports on the role of
each virus in the pathogenicity of HBV/HDV infection.
Some reports suggest that the activity of liver disease is
mainly due to HDV [13-16] while others implicate hepa-
titis B virus, regardless of the levels of HBV DNA, in the
aggressive nature and progression of disease [17]. In stu-
dies from Europe, HDV has frequently been shown to
suppress HBV replication [18,19], and 70-90% of
patients with hepatitis D are hepatitis B e antigen
(HBeAg) negative, with low serum levels of HBV DNA.
However, despite this influence of HDV on HBV, 15-
30% of patients with hepatitis D are HBeAg and/or
HBV DNA positive.
There is no data, to our knowledge, on the character-
istics and impact of hepatitis delta virus on hepatitis B
virus infection and its spectrum of diseases from South
Asia. The aim of this study was to investigate the virolo-
gical and clinical characteristics of patients infected with
HBV/HDV infection in two large tertiary care centers of
Pakistan.
Methods
Patients’ characteristics
We conducted this study prospectively in patients seen
at the Aga Khan University Hospital (AKUH), Karachi
and Isra University Hospital, Hyderabad, Pakistan. Both
hospitals are situated in the province of Sindh and serve
as main tertiary care centers located in the southern
part of Pakistan, which is among the largest countries of
South Asia; it represents 30% of the population of this
region. Each year approximately half a million patients
visit the out-patient clinics and 45,000 are managed as
in-patients in the different wards of these two hospitals.
The AKUH laboratory has 189 collection centers all
around the country including 07 in Hyderabad where
the samples are collected and transported to the central
laboratory in Karachi for processing.
We identified 2455 HBsAg positive patients and checked
their HBV DNA PCR by qualitative methods from 2005 to
2009 at these two centers. Out of 2455 patients with a
reactive HBsAg, 480 patients with a positive HBV DNA
PCR underwent testing for anti-HDV and quantitative
HBV DNA PCR assay. HDV infection was defined by posi-
tive anti-HDV results. Demographics and physical findings
were recorded in all patients with or without HDV co-
infection prior to the start of any anti-viral treatment.
Biochemical and virological markers
Serum samples of all patients were tested for biochemical
parameters including complete blood count, total biliru-
bin, ALT, alkaline phosphatase, creatinine and prothrom-
bin time (PT), by standard laboratory methods. Upper
limit of ALT was 55 IU/L for men and 33 IU/L for
women. Serological tests conducted were qualitative
HBsAg, HB core IgG, HBeAg, anti-HBe, anti-HDV by EIA
assay (Chicago, IL, USA) and anti-HCV by ELISA-3 in all
included patients during their visits to clinic within six
months. All the biochemical, serologic and virological tests
from the two centers was processed in the central clinical
laboratory at the Aga Khan University Hospital, Karachi.
HBV DNA PCR qualitative analysis was performed by
Cobas Amplicor HBV Monitor (Roche Diagnostic Sys-
tems, Basel, Switzerland) with a lower detection limit of
500 copies/ml. We considered the value of the qualita-
tive PCR detectable to be ≤10 2. All these patients were
subsequently tested for quantitative HBV DNA PCR
assay (RoboGene HBV DNA Quantification Kit, Triple-
Hyb version, Leipzig, Delitzscher Str, Germany) and
anti-HDV testing. Quantitative HBV DNA PCR has the
lower limit of detection of approximately 1000 (> 10 2)
copies/ml. HDV RNA PCR qualitative assay (Roche
Diagnostics, USA) could only be checked in 49 patients
with HDV co-infection as this test was not available in
early part of the study in our laboratory.
HDV RNA was isolated from patients’ serum samples
by High Pure Viral RNA isolation kit, according to the
manufacturer’s instructions (Roche Diagnostics, USA).
RNA was eluted from spin columns provided with the
kit in sterile nuclease free water and stored at -80 °C
until further analysis. Later, RNA samples were reverse
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transcribed into cDNA using 1st Strand cDNA Synthesis
Kit for RT-PCR (Roche Diagnostics, USA). Briefly,
cDNA mix consisted of reaction buffer containing 5
mM MgCl2, R NA, random primers, 50 units RNAse
inhibitor and AMV reverse transcriptase. The reaction
was carried out for 90 min at 42 °C in a thermal cycler.
The resulting cDNA was amplified with sequence speci-
fic primers for HDV. The amplified products were sepa-
rated on a 1.5% agarose gel and a 400 bp product
indicated the presence of HDV in the sample. To moni-
tor the quality of the assay in each test run, both nega-
tive and positive controls were included [20].
Abdominal ultrasound of all included patients was
performed for the assessment of echo-texture, size and
margins of liver & spleen and for features suggestive of
portal hypertension. Stages of liver disease such as those
with or without cirrhosis were identified on clinical and/
or biochemical laboratory parameters along with ultra-
sonological findings.
Spectrum of hepatitis virus infection
480 hepatitis B patients with or without HDV infection
were categorized into four clinical stages: (1) Asympto-
matic carrier (AC) - patients were clinically asympto-
matic with hepatitis B e antigen (HBeAg) negative,
serum HBV DNA levels are < 105 and normal serum
ALT levels (at least 2 ALT values in the previous 6
months follow-up). (2) Immune-tolerant phase (IP) -
patients were asymptomatic with hepatitis B e antigen
(HBeAg) positive or negative, high serum HBV DNA
levels (≥ 105) and normal serum ALT levels (at least 2
ALT values in the previous 6 months). (3) Chronic
active hepatitis B (CAH) - patients may be sympto-
matic or asymptomatic with hepatitis B e antigen
(HBeAg) positive or negative, with raised serum HBV
DNA PCR and ALT levels (at least 2 ALT values above
ULN in the previous 6 months). These patients have no
evidence of cirrhosis on clinical, biochemical laboratory
parameters along with ultrasonological examination. (4)
Compensated liver cirrhosis (CLC) - patients may be
symptomatic or asymptomatic with hepatitis B e antigen
(HBeAg) positive or negative, whatever are their serum
HBV DNA levels, and ALT levels in the previous 6
months. These patients have evidence of cirrhosis iden-
tified on clinical, and/or biochemical laboratory para-
meters along with abdominal ultrasound examination
[21,22]. HDV co-infection-patients with anti-HDV reac-
tive and/or HDV RNA PCR detectable [23].
Exclusion criteria
We excluded patients (1) under the age of 14 years, (2)
with decompensated liver disease (defined by a serum
bilirubin more than 2.5 times the upper limit of normal;
prothrombin time > 3 seconds compared with control;
serum albumin < 2.5 g/dl; or a history of ascites, variceal
hemorrhage or hepatic encephalopathy or hepatocellular
carcinoma (3) with evidence of liver disease due to
another etiology such as hepatitis C, metabolic liver dis-
ease or autoimmune liver disease, (4) history of use of
hepatotoxic drugs and (5) patients with multiple infec-
tions (i.e. HBV, HDV, HIV and HCV).
This study was approved by the Ethics Review Com-
mittee (ERC) of Aga Khan University Hospital.
Statistical Analysis
Statistical analysis was performed using the Statistical
Package for Social Science SPSS (Release 17.0, standard
version, copyright © SPSS; 1989-02). Descriptive analysis
was performed for demographic and clinical features;
results were presented as mean ± standard deviation for
quantitative variables and number (percentages) for qua-
litative variables.
A descriptive analysis was performed for all patients
with HBsAg positive along with HBV DNA PCR detect-
able. To determine any statistical difference, data were
divided into HBeAg positive and HBeAg negative sub-
groups. The two groups were compared for demographic
and laboratory parameters. In HBeAg positive patients’
comparison was conducted between HBV/HDV co-infec-
tion and HBV mono-infection patients; similar compari-
son was performed for the HBeAg negative patients. Chi-
square test and Fisher’s exact test were used for categori-
cal variables, while the independent sample test was used
for numerical variables. All p-values were two sided and
considered as statistically significant if < 0.05.
Results
A total of 2455 HBsAg positive patients were checked
for HBV DNA PCR by qualitative assay; 480 (19.5%)
patients with HBV DNA PCR by qualitative assay were
eligible for inclusion in this study. HBV DNA PCR
quantitative assays and anti-HDV serology was checked
in all these patients.
Virology and HBV DNA PCR assays
Overall, there were 398 (82.9%) males with a mean age
of 33 ± 12.5 years. Mean HBV DNA PCR levels was 1.9
× 10 7 ± 1.2 × 10 8 copies/ml. There were 169/480
(35.2%) patients with HBV/HDV co-infection.
Overall, the HBV DNA PCR assay above 1000 (> 102)
copies/ml was reported in 294 (61%) while rest have
≤102 copies/ml. Moreover, higher HBV DNA levels of ≥
105 copies/ml were found in 103 (21.5%), while < 105 in
377 (78.5%) patients; table 1.
HBeAg positive versus HBeAg negative patients
Out of 480 patients, 164 (34.6%) were HBeAg positive
and 316 (65.4%) HBeAg negative. We found that HBeAg
Mumtaz et al. Virology Journal 2011, 8:312
http://www.virologyj.com/content/8/1/312
Page 3 of 8
positive patients were younger (30 ± 13.3 years) as com-
pared to HBeAg negative (34.3 ± 11.9 years); p-value =
< 0.001. ALT levels above upper limit of normal (ULN)
were found in 91 (55.5%) HBeAg positive as compared
to 142 (45%) among HBeAg negative group; (p-value =
0.02). Moreover, the level of HBV DNA PCR was ≥ 105
copies/ml in 83 (51%) patients with HBeAg positive as
compared to 20 (15.3%) among HBeAg negative, (p-
value < 0.001); table 1.
HBeAg positive patients have raised ALT and higher
HBV DNA levels as compared to HBeAg negative.
HDV infection and ALT levels
Mean ALT levels in our study population were 66 ± 73
IU. Moreover, mean ALT in patients with HBV/HDV
co-infection was 74.3 ± 76.7 IU as compared to 61.6 ±
70.3 IU in HBV mono-infection; (p-value = 0.06).
Furthermore, there were 96/169 (56.8%) patients with
raised ALT in HBV/HDV co-infection group as com-
pared to 137/311 (44%) in HBV mono-infection, (p-
value 0.008); table 2. Overall HBV/HDV co-infection
patients have raised ALT levels.
Among HBeAg positive patients mean ALT was 74 ± 79
IU; 91/164 (55.5%) patients had a raised ALT above the
ULN. Out of 164 patients with positive HBeAg, 41 patients
had a HBV/HDV co-infection, while 123 had HBV mono-
infection. Of the patients with HDV co-infection (n = 41),
25/41 (61%) had raised ALT, while in patients with HBV
mono-infection (n = 123), 66 (53.7%) patients had raised
ALT level; (p value = 0.41); table 3. Among patients with
raised ALT, 47 (51.6%) had HBV DNA level ≥ 105 while
44 (48.4%) had a HBV DNA level < 105; (p-value = 0.76).
Among HBeAg positive patients, HBV/HDV co-infec-
tion has no affect on ALT and HBV DNA levels.
Among HBeAg negative patients, mean ALT was 62 ±
69 IU; 142/316 (45%) had raised ALT level.
Table 1 Characteristics of study population in HBeAg positive and negative patients
Total n = 480 HBeAg positive n = 164 HBeAg negative n = 316 p value
Age, years 33 ± 12.53 30 ± 13.36 34.28 ± 11.87 < 0.001
Gender
Male 398(82.9) 138(84.1) 260(82.3) 0.60
Female 82(17.1) 26(15.9) 56(17.7)
ALT 66.07 ± 72.83 73.95 ± 79.04 61.98 ± 69.16 0.10
Median ALT 38(9-500) 42(9-500) 35(10-496)
Normal 247 (51.5) 73(44.5) 174(55.1) 0.02
Raised 233 (48.5) 91(55.5) 142(44.9)
HBV DNA level
≥ 10e5 103 (21.5) 83 (50.9) 20 (15.3) < 0.001
< 10e5 377 (78.5) 80 (49.1) 111 (84.7)
Anti HDV
Reactive 169 (35.2) 41 (25) 128 (40.5) 0.001
Non reactive 311 (64.8) 123 (75) 188 (59.5)
HDV RNA qualitative
Positive 49 (10.2) 7 (5.7) 42 (13.8) < 0.001
Negative 67 (14) 7 (5.7) 60 (19.7)
HBV stage
Carrier of HBV 143 (29.8) 0 143 (45) < 0.001
Chronic active HBV 185 (38.5) 75 (45.7) 110 (34.8)
Compensate cirrhosis with HBV 72(15) 22 (13.4) 50 (15.8) 0.48
Immunotolerant phase 80 (16.7) 60 (36.6) 20 (6.3) NS
NS = not significant.
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In this group mean ALT was 75 ± 79 in HBV/HDV
co-infection as compared to 53 ± 60.3 among HBV
mono-infection patients, (p-value = 0.009). Moreover,
ALT levels were above ULN in 71/128 (55.5%) with
HBV/HDV co-infection as compared to 71/188 (37.8%)
among HBV mono-infection; (p-value = 0.002); table 4.
Among patients with raised ALT, 12 (8.5%) had a HBV
DNA level ≥ 105 while 130 (91.5%) had a HBV DNA
level < 105 copies/ml (p-value = 0.16).
Among HBeAg negative patients, HBV/HDV co-infec-
tion is associated with raised ALT levels, but ALT levels
were not directly proportionate to HBV DNA levels.
HDV infection and HBeAg status
A large proportion of patients with HBV/HDV co-infec-
tion had HBeAg negative (128/169; 75.7%) disease, as
compared to HBV mono-infection (188/311; 60.5%);
p-value 0.001.
Among HBeAg positive patients, 41/169 (24.3%) had
HBV/HDV co-infection. The distribution of age, gender,
ALT and HBV DNA PCR levels were similar among the
two groups. Furthermore, the spectrum of hepatitis B
disease was also similar in both groups; table 3.
HBV/HDV co-infection has no implications on the
HBV DNA PCR as well as the spectrum of liver disease.
Table 3; Figure 1.
Among HBeAg negative patients, 128/316 (40.5%) had
HBV/HDV co-infection. HBV DNA PCR levels were
equally distributed in the two groups of patients (table 2).
Patients with HBV/HDV co-infection had more severe
liver disease - compensated liver cirrhosis was present in
Table 2 Clinical and laboratory parameters in HDV
positive and negative patients
HDV positive n =
169
HDV negative n =
311
p
value
Age (years) 32.74 33 0.88
Sex-male 136 (80.5%) 262 (84.2%) 0.29
ALT-mean 74.3 ± 76.7 61.6 ± 70.3 0.06
ALT normal 73 (43.2%) 174 (55.9%) 0.008
ALT raised 96 (56.8%) 137 (44.1%)
HBeAg positive 41 (24.3%) 123 (39.5%) 0.001
HBeAg negative 128 (75.7%) 188 (60.5%)
Mean HBV DNA
levels
HBV DNA > 105 23 (13.6%) 80 (25.7%) 0.002
HBV DNA < 105 146 (86.4%) 231 (74.3%)
HBV stages
Carrier 45 (26.6%) 98 (31.5%) 0.003
Chronic active HBV 73 (43.2%) 112 (36%)
Compensate
cirrhosis
34 (20.1%) 38 (12.2%) 0.02
Immunotolerant
phase
17 (10.1%) 63 (20.3%) NS
NS = not significant.
Table 3 Descriptive characteristics of HBeAg positive
patients (n = 164) in patients with HBV/HDV co-infection
and HBV mono-infection
HDV Positive n =
41
HDV
Negative
n = 123
p
value
Age, years 29 ± 8.85 30.34 ±
14.53
0.44
Gender-male 34 (82.9%) 104 (84.6%) 0.80
Male 34 (82.9) 104 (84.6) 0.80
Raised ALT 25 (61) 66 (53.7) 0.41
Mean ALT 72.2 ± 70.7 74.5 ± 82 0.87
HBV DNA level
≥ 10e5 17 (41.5) 66 (54.1) 0.17
< 10e5 24 (58.5) 57 (46.3)
Spectrum of HBV:
Carrier of HBV 00 7 (5.7) 0.54
Chronic active HBV 21 (51.2) 54 (43.9) NS
Compensate cirrhosis with
HBV
7 (17.1) 15 (12.2) NS
Immunotolerant phase 12 (29.3) 48 (39) NS
NS = not significant.
Table 4 Descriptive characteristics of HBeAg negative
patients (n = 316) in patients with HBV/HDV co-infection
and HBV mono-infection
HDV Positive n =
128
HDV
Negative
n = 188
p
value
Age, years 34 ± 11.3 34.5 ± 12.2 0.63
Gender-Male 102(79.7) 158(84) 0.32
Raised ALT 71(55.5) 71(37.8) 0.002
HBV DNA Positive 41(32.3) 74(39.4) 0.20
HBV DNA level
≥ 10e5 6(11.5) 14(17.7) 0.32
< 10e5 122(95.3) 174(92.6)
Cirrhosis 27(21.1) 23(12.2) 0.03
HBV stage
Carrier of HBV 44(34.4) 92(48.9) 0.009
Chronic active HBV 52(40.6) 58(30.9)
Compensate cirrhosis with
HBV
27(21.1) 23(12.2) NS
Immunotolerant phase 5(3.9) 15(8) NS
NS = not significant.
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27 (21%) as compared to 23 (12%) among HBV mono-
infection; p-value = 0.03. Similarly, chronic active hepati-
tis (CAH) in 52 (40.6%) patients with HBV/HDV co-
infection as compared to 58 (31%) without it; (p-value =
0.009); table 4; Figure 1
Among HBeAg negative patients with HBV/HDV co-
infection, severe form of liver disease is seen, though
HBV DNA levels were equally distributed, suggesting
that HDV is actively involved in the progression of liver
disease.
HDV infection and HBV DNA quantitative assays
Overall levels of HBV DNA PCR < 105 was found in
146 (86.4%) HBV/HDV co-infected patients as com-
pared to 231 (74.3%) HBV mono-infection (p-value =
0.002); table 1b. However, this suppression of HBV
DNA levels in HBV/HDV co-infection patients was
independent of the HBeAg status; table 3 &4 and Figure
2 &3.
This suggests presence of HBV/HDV co-infection sup-
presses HBV DNA levels.
HDV infection and clinical spectrum
The details of demographics, baseline laboratory para-
meters and distribution of spectrum of hepatitis B
related liver disease is shown in table 1. There were 73/
169 (43%) patients with chronic active hepatitis B
(CAH) among HBV/HDV co-infection as compared to
112/311 (36%) among HBV mono-infection; (p-value =
0.003). Similarly there were 34 (20%) patients with com-
pensated liver cirrhosis (CLC) among HBV/HDV co-
infection as compared to 38 (12%) in HBV mono-infec-
tion group; p-value = 0.02. We found most asympto-
matic carrier and immune-tolerant hepatitis B patients
in HBV mono-infection group (table 1). HBV/HDV co-
infection produces more severe clinical spectrum of liver
disease. Moreover, this impact of HBV/HBV co-infec-
tion is more marked in HBeAg negative patients as
already mentioned above.
Discussion
This is the largest report that we know on viral charac-
teristics of hepatitis delta virus infection, recruited at
two centers of Pakistan which represent a robust popu-
lation of South Asia. In particular, data of HBeAg posi-
tive patients is limited globally. HBV patients can be
simultaneously infected by delta virus, as the source of
transmission of both viruses is same and results in a
severe form of liver disease. There are variable reports,
as to which virus is actively responsible for liver disease
in patients with chronic HDV infection - HBV or HDV?
[14-17]. We designed this study to examine the effects
of HBV/HDV co-infection on ALT, HBeAg status and
HBV DNA PCR levels, in addition to the different spec-
trums of hepatitis B related liver disease. Our present
study showed that 35.2% of patients had HBV/HDV co-
infection. We published an epidemiological survey of
HDV prevalence in 2005. This survey included 8721
HBV patients over 14 years of age and tested for anti-
HDV antibody from all over the country. The HDV
Figure 1 Comparison of spectrum of hepatitis B related liver
diseases in patients with HBV/HDV co-infection and HBV
mono-infection, based on HBeAg status.
Figure 2 Showing significant HBV DNA levels suppression in
patients with HBV/HDV co-infection.
Figure 3 Showing absence of suppression of HBV DNA PCR
levels in patients with HBV/HDV co-infection with HBeAg
negative disease
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prevalence was found to be 16.6% [9]. Higher frequency
of HDV co-infection in this report could have been due
to a selection bias as reported by Seetlani et al [24].
In our present study, majority of patients with HBV/
HDV co-infection were young males, which is similar to
earlier studies from Italy [25], and Pakistan [9]. One
possible explanation could be the higher rate of intrave-
nous drug abuse in this cohort of patients in the devel-
oped countries, and therapeutic injections with
contaminated needles and vertical transmission in the
developing world [26]. The mean age of cirrhotic HDV
patients was also younger than that of cirrhotic HBV
patients without HDV. These findings indicate the
greater severity of chronic HDV infection than chronic
HBV infection alone.
Our study shows that patients with HBV/HDV co-
infection have raised ALT levels and suppressed HBV
DNA levels as compared to HBV mono-infection. More-
over, HBV patients with HBeAg positive disease regard-
less of their HDV status have raised ALT levels and
high HBV DNA levels as compared to HBeAg negative
patients. Interestingly, we observed that in HBeAg posi-
tive patients, ALT and HBV DNA levels were equally
distributed among HBV/HDV co-infection and HBV
mono-infection patients. It seems that among HBeAg
positive patients HBV/HDV co-infection has no impact
on the HBV DNA levels.
Contrary to HBeAg positive group, among HBeAg
negative patients HBV/HDV co-infection is associated
with raised ALT levels, but ALT levels were not corre-
lated to high HBV DNA levels. Among HBeAg negative
patients with HBV/HDV co-infection, a more severe
spectrum of liver disease was seen, although the HBV
DNA level was low. This would suggest that HDV is
actively involved in progress of liver disease.
Our study also shows that HBV/HDV co-infection,
suppresses hepatitis B virus. HBV/HDV co-infection
produces a more aggressive disease as compared to
mono-infection with hepatitis B. This has also been
reported in many studies [14-16,23] for HBeAg negative
patients.
Furthermore, HBeAg, a marker of viral replication,
was found in a higher percentage of patients with HBV
mono-infection as compared to HBV/HDV co-infection,
which was also noted in our study. It has also been well
documented that the difference in HBV genotype affects
the prevalence of HBeAg and the replication level of
HBV [27,28]. HBV genotype B is reported to be asso-
ciated with HBeAg negativity and a lower viremia level.
Furthermore, certain HDV strains, like HDV genotype II
are associated with more mild liver disease. Correlation
between HDV genotypes and HBV replication however
remains largely unknown.
The main mechanism of inhibition of viral replication
in HBV infection is not cytotoxicity against infected
hepatocytes but rather the secretion of inhibitory cyto-
kines like interferon-gamma, interferon-alpha or TNF-
alpha. HDV proteins inhibit HBV replication by trans-
repressing its enhancers and by trans-activating the
IFN-alpha-inducible MxA gene [29].
Individuals having HBV/ HDV co-infection may have
a more severe acute disease and higher risk of fulminant
hepatitis [14-16]. It is observed that most of the indivi-
duals infected with HDV develop the chronic form of
the disease, and in approximately 80% of these indivi-
duals the chronic HDV infection progresses to cirrhosis
within 5-10 years [30]. This observation is also noted in
our HBV/HDV co-infection patients. HBV/HDV co-
infection showed a several fold increase in progression
of chronic hepatitis to cirrhosis (p-value 0.003) as com-
pared to HBV mono-infection.
In conclusion, we found that HBV/HDV co-infection
results in suppression of hepatitis B virus. Patients with
HBV/HDV co-infection with negative HBeAg status
demonstrate a severe spectrum of liver disease. Due to
limited and ineffective treatment options for the treat-
ment of HBV/HDV infection our main focus must be
on the prevention of the disease. While the prevalence
of HDV is showing a decreasing trend globally, it is
important to realize that globalization and increasing
migratory fluxes are major challenges and HDV will not
be controlled adequately unless HBV is brought under
control in areas with high prevalence.
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